From weeks to hours: Rapid new test speeds up brain tumour diagnosis

KUALA LUMPUR, 25 SEPTEMBER 2026 —

NHS Revolutionizes Brain Tumour Diagnosis: Genomic Test Cuts Wait from Weeks to Hours, Transforming Patient Care

The NHS’s rapid sequencing technology, piloted across five specialist centres in England, marks a global first in real-time tumour classification, with results already guiding surgical strategies mid-operation. For patients like Steve Palmer, 55, of Nottingham, the innovation eliminated weeks of anxiety after collapsing at the gym and discovering a grade 4 glioblastoma.

"Getting that quick diagnosis removed weeks of anxiety," Palmer told the BBC, adding that the swift confirmation let him "get on with the next phase of treatment and recovery."

The test, developed using Oxford Nanopore’s shoebox-sized sequencing machine and software from the University of Nottingham, analyzes tumour DNA through a nanopore—a microscopic hole that decodes the genetic fingerprint within minutes. In Palmer’s case, results were confirmed just 20 minutes into the procedure, allowing surgeons to adjust their approach immediately. Consultant neurosurgeon Stuart Smith called the technology "almost magical," noting that traditional molecular analysis could take six to eight weeks.

"For some tumour types, surgery needs to be radical to remove every last bit," he explained. "For others, it’s too aggressive, so we’d be more cautious to avoid brain damage."

With over 12,000 new brain tumour cases annually in the UK—making it the leading cancer killer for those under 40—the pilot involves Nottingham University Hospitals, Birmingham’s University Hospitals, Great Ormond Street Hospital, King’s College Hospital, and Newcastle Hospitals. Expansion to Bristol, Oxford, Leeds, and Manchester is planned. Prof Frankie Swords, NHS medical director, hailed it a "world first," emphasizing that no other health system is deploying the technology across multiple hospitals.

"A faster diagnosis means patients can start the right treatment or access clinical trials sooner," she said, while Prof Dame Sue Hill, chief scientific officer, stressed the potential to make rapid genomic testing routine.

The shift from weeks to hours is already reshaping care. Dr Simon Paine, a neuropathologist, contrasted the nanopore’s precision with traditional microscopy, calling it a "comprehensive molecular classification" that surpasses even expert guesswork. Smith added that the full genetic profile could accelerate access to clinical trials. For families, the change is profound: Palmer’s wife, who endured months of uncertainty before, now faces a clearer path.

"It’s not the result we wanted, but at least we know what we’re dealing with," he said.

The pilot builds on earlier work in Nottingham and Birmingham, with NHS England positioning the test as a cornerstone of its genomics strategy. While the technology remains experimental, its success could redefine global standards for neuro-oncology, offering Malaysia and Southeast Asia a model for accelerating diagnostics in resource-strained healthcare systems.

With brain tumours carrying a dismal prognosis without early intervention, the UK’s leap forward underscores how rapid innovation can turn the tide in life-or-death races against time.